TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22711898

Group type: EXPERIMENTAL
Intervention: Rizatriptan (5 mg for < 40 kg, 10 mg for ≥ 40 kg)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study: 20035922

Group type: EXPERIMENTAL
Intervention: Aspherical intraocular lens (Akreos Advanced Optic)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Spherical intraocular lens (Akreos Fit)
Number of subjects: 25
Study: 18272093

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg morphine then 0.025 mg/kg every 5 minutes (group A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg morphine then 0.05 mg/kg every 5 minutes (group B)
Number of subjects: 106
Study: 15755947

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full‐field digital mammography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer‐aided detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical breast examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast self‐examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 0
Study: 12778779

Group type: COMPARATOR
Intervention: Infusions taken directly from a warming box in the ambulance (Group A, n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Infusions taken from the warming box and packed in an insulation device (Group B, n = 25)
Number of subjects: 50
Study: 9704787

Group type: EXPERIMENTAL
Intervention: Fetal plasma interleukin‐6 concentrations > 11 pg/mL
Number of subjects: 157

Group type: COMPARATOR
Intervention: Fetal plasma interleukin‐6 concentrations ≤ 11 pg/mL
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Overall prevalence of severe neonatal morbidity among survivors
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Fetal plasma interleukin‐6 concentrations
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Fetal plasma interleukin‐6 concentrations in subset of patients (73 fetuses delivered within 7 days of cordocentesis)
Number of subjects: 157
Study: 7702028

Group type: EXPERIMENTAL
Intervention: Pasta meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Parboiled rice meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-GI meals (control)
Number of subjects: 10
Study: 2674246

Group type: EXPERIMENTAL
Intervention: Normal weight patient
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Obese patient
Number of subjects: 100

Group type: COMPARATOR
Intervention: Male patient
Number of subjects: 100

Group type: COMPARATOR
Intervention: Female patient
Number of subjects: 100
Study: 67805

Group type: EXPERIMENTAL
Intervention: Individualized audiovisual patient education program about digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditionally-educated patients
Number of subjects: 0
Study: 29513248

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy with 3-day substitution therapy of deficient factors VIII or IX
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group of 20 non‐hemophiliac patients with liver cirrhosis
Number of subjects: 22
Study: 26918279

Group type: EXPERIMENTAL
Intervention: TAS-102 (35 mg/m²) administered in a single dose during pharmacokinetic phase and twice-daily doses in 28-day cycles during repeated administration phase.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: TAS-102 (twice-daily doses) during repeated administration phase.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: TAS-102 (postprandial administration).
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: TAS-102.
Number of subjects: 9
Study: 24886107

Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 300

Group type: COMPARATOR
Intervention: Multicomponent Training
Number of subjects: 300
Study: 22226329

Group type: EXPERIMENTAL
Intervention: Exercise training (8-week aerobic exercise program)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (standard medical care and follow-up)
Number of subjects: 38
Study: 20381653

Group type: EXPERIMENTAL
Intervention: Medtronic AVE Interceptor Saphenous Vein Graft Filter System (EPD)
Number of subjects: 748

Group type: COMPARATOR
Intervention: GuardWire or FilterWire EPD (Control)
Number of subjects: 748
Study: 18760041

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study: 16463831

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (20 mmol over 10 min followed by an infusion of 4 mmol/h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 18
Study: 12431857

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10398629

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg tablet) once daily at bedtime for up to 12 weeks
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo once daily at bedtime for up to 12 weeks
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 7570431

Group type: EXPERIMENTAL
Intervention: Once weekly physiotherapy (group A) after initial twice weekly sessions for 3 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Once monthly physiotherapy (group B) after initial twice weekly sessions for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: No rehabilitation (control group C)
Number of subjects: 36
Study: 2112131

Group type: EXPERIMENTAL
Intervention: 4% lidocaine inhalation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 18
Study: 378094

Group type: EXPERIMENTAL
Intervention: Inderectic (propranolol 80 mg and bendrofluazide 2.5 mg, given twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Free combination of propranolol and bendrofluazide (given as separate tablets)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bendrofluazide alone
Number of subjects: 21
Study: 6840831

Group type: EXPERIMENTAL
Intervention: liver-solution with 45% branched chain amino acids
Number of subjects: 18

Group type: COMPARATOR
Intervention: conventional solution with 10.5% branched chain amino acids
Number of subjects: 18
Study: 29290078

Group type: EXPERIMENTAL
Intervention: ACT target of 300 seconds
Number of subjects: 68

Group type: COMPARATOR
Intervention: ACT target of 450 seconds
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 30591575

Group type: EXPERIMENTAL
Intervention: Daily SMS quizzes
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Daily SMS quizzes with daily readings and online CME courses
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study: 27465329

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 24506265

Group type: EXPERIMENTAL
Intervention: 4 ml 1% methylene blue and 16 ml 0.5% marcaine
Number of subjects: 67

Group type: COMPARATOR
Intervention: 16 ml 0.5% marcaine and 4 ml saline (placebo)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 67
Study: 21450562

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: More intensive NRT at week 4
Number of subjects: 481
Study: 19679221

Group type: EXPERIMENTAL
Intervention: Glucosamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups (Glucosamine, Ibuprofen, Placebo)
Number of subjects: 36
Study: 17927638

Group type: EXPERIMENTAL
Intervention: Innovative manual toothbrush
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional toothbrush
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 30
Study: 15843221

Group type: EXPERIMENTAL
Intervention: 7-oxo-dehydroepiandrosterone (25 mg daily transdermally for 8 days)
Number of subjects: 21
Study: 12079252

Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus cognitive‐behavioral mood management training (CBT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Behavioral counseling (BC)
Number of subjects: 51
Study: 9791752

Group type: EXPERIMENTAL
Intervention: Vaccinated children (PRP-T vaccine)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-vaccinated children
Number of subjects: 102
Study: 7881681

Group type: COMPARATOR
Intervention: Standard physical therapy (STD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of standard therapy with exercise (EX)
Number of subjects: 35
Study: 2757665

Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Midazolam 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 840117

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 1463

Group type: COMPARATOR
Intervention: Control (no streptokinase)
Number of subjects: 1463
Study: 31170712

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (Bard) 20 mg once daily
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study: 27604584

Group type: EXPERIMENTAL
Intervention: Imageless navigation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Estimation by eye and palpation (control)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both groups (navigated and control)
Number of subjects: 135
Study: 26580249

Group type: EXPERIMENTAL
Intervention: Neostigmine at appearance of the fourth twitch of a 'train‐of‐four'
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neostigmine at loss of fade to train‐of‐four
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neostigmine at loss of fade to double‐burst stimulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison of recovery times
Number of subjects: 48
Study: 23934045

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib injected intravenously 30 min before surgery and every 12 h for 2 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incision-local block with 5 ml of 0.5% ropivacaine and 20 ml of physiological saline every 12 h for 2 days
Number of subjects: 40
Study: 21114583

Group type: EXPERIMENTAL
Intervention: Combined metformin and clomiphene citrate (CC)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 282
Study: 20003788

Group type: EXPERIMENTAL
Intervention: Remifemin 20 mg bid po for 12 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Tibolone 2.5 mg qd po for 12 weeks
Number of subjects: 180
Study: 16941068

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (single dose)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cefuroxime axetyl (5-day regimen)
Number of subjects: 84
Study: 15532067

Group type: EXPERIMENTAL
Intervention: Test bromazepam formulation (6 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Reference bromazepam formulation (6 mg)
Number of subjects: 27
Study: 11026946

Group type: EXPERIMENTAL
Intervention: Couple therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Antidepressant drugs
Number of subjects: 77
Study: 8970891

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Social domain
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Biomedical domain
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Care domain
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: General quality of life
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 958
Study: 1315212

Group type: EXPERIMENTAL
Intervention: WR-2721 (100 mg/enema to 450 mg/enema)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no WR-2721)
Number of subjects: 31
Study: 3876591

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphamethoxazole treatment in achlorhydric and postgastrectomy patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hydrogen (H2) breath test
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standardized meal before H2 breath test
Number of subjects: 51

Group type: COMPARATOR
Intervention: Correlation of total bacterial concentration in gastric juice
Number of subjects: 51
Study: 30860407

Group type: EXPERIMENTAL
Intervention: Natural Grass (NG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Artificial Turf (AT)
Number of subjects: 9
Study: 30519081

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMGBF) associated with isometric exercise
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isometric exercise without biofeedback
Number of subjects: 46
Study: 27632841

Group type: EXPERIMENTAL
Intervention: Hip- or knee-muscle-strengthening rehabilitation
Number of subjects: 157
Study: 23965225

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed-dose via single-use injection device)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Intravenous trastuzumab
Number of subjects: 248

Group type: COMPARATOR
Intervention: No preference
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab
Number of subjects: 248
Study: 20194384

Group type: EXPERIMENTAL
Intervention: Pain‐Free (Parkell, Edgewood, N.Y.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Seal & Protect (Dentsply DeTrey, Konstanz, Germany)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: BisBlock (Bisco, Schaumburg, Ill.)
Number of subjects: 11
Study: 18062976

Group type: EXPERIMENTAL
Intervention: STAEST (2g/day stanols)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (spread with no added stanols)
Number of subjects: 19
Study: 16604824

Group type: EXPERIMENTAL
Intervention: Selective brain cooling (SBC)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mild systemic hypothermia (MSH)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 14600686

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg of methylprednisolone sodium succinate (MP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of methylprednisolone sodium succinate (MP)
Number of subjects: 26
Study: 10912539

Group type: EXPERIMENTAL
Intervention: Daily oral calcitriol (10 ng/kg per day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intermittent oral calcitriol (35 ng/kg given twice a week)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 59
Study: 8982887

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg plus propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg plus propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg plus propofol
Number of subjects: 40
Study: 1550367

Group type: EXPERIMENTAL
Intervention: Isotretinoin cream (0.05% for 3 months, then 0.1% for 6 months)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 326
Study: 6400534

Group type: EXPERIMENTAL
Intervention: Cefsulodin alone (31 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefsulodin in combination with a nonantipseudomonal antibiotic (9 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefsulodin (2-8 g/day) for 4-37 days (25 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefsulodin (4-12 g/day) for 5-45 days (15 patients)
Number of subjects: 40
Study: 30767663

Group type: EXPERIMENTAL
Intervention: BioFreedom biolimus‐eluting stents (BES)
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Cre8 amphilimus‐eluting stents (AES)
Number of subjects: 1280
Study: 29063703

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Triamcinolone (8 mg)
Number of subjects: 25
Study: 27289365

Group type: EXPERIMENTAL
Intervention: TFMPP (60 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: BZP (200 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: BZP + TFMPP (100 mg/30 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (20 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: All drug treatments
Number of subjects: 82
Study: 25483691

Group type: EXPERIMENTAL
Intervention: Cervarix®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gardasil®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervarix® and Gardasil®
Number of subjects: 0
Study: 23134924

Group type: EXPERIMENTAL
Intervention: Oral hydration therapy (2 liters of water within 2 hours, then 2 liters daily for 7 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral hydration therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine water intake (control group)
Number of subjects: 64
Study: 20533037

Group type: EXPERIMENTAL
Intervention: +BOPT
Number of subjects: 36
Study: 18957869

Group type: EXPERIMENTAL
Intervention: Low-animal-protein diet (LAPD)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: High-fiber diet (HFD)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: LAPD
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: HFD
Number of subjects: 175
Study: 16319109

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg i.v. bolus 30 min before cisplatin on Day 1 and a 0.1 mg tablet for Days 2 to 5)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Granisetron (3 mg i.v. infusion 30 min before cisplatin on Day 1 and a 1 mg tablet for Days 2 to 5)
Number of subjects: 73
Study: 12830468

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 300 mg ascorbic acid
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no ascorbic acid)
Number of subjects: 35
Study: 10792412

Group type: EXPERIMENTAL
Intervention: TENS stimulation applied for 15 min over the sural nerve in the left leg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no TENS stimulation)
Number of subjects: 50
Study: 8105737

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cortical bone mineral density
Number of subjects: 40
Study: 3628857

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide 1000 mg and hydrocortisone 40 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aminoglutethimide 1000 mg, hydrocortisone 40 mg and fluoxymesterone 20 mg daily
Number of subjects: 50
Study: 29605123

Group type: EXPERIMENTAL
Intervention: Training of radiographers in RSA imaging technique
Number of subjects: 0
Study: 27423556

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin (dual therapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin (monotherapy)
Number of subjects: 100
Study: 25995278

Group type: EXPERIMENTAL
Intervention: Vitamin B-12 intake of ∼8.6 μg/d (mixed diet plus prenatal multivitamin supplement)
Number of subjects: 75
Study: 23809021

Group type: COMPARATOR
Intervention: Supreme Laryngeal Mask Airway (S‐LMA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (P‐LMA)
Number of subjects: 60
Study: 21508941

Group type: EXPERIMENTAL
Intervention: screening with STOPP/START criteria followed up with recommendations to attending physicians
Number of subjects: 400

Group type: COMPARATOR
Intervention: usual pharmaceutical care (control)
Number of subjects: 400
Study: 19390971

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 100
Study: 16919533

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nisoldipine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and nisoldipine
Number of subjects: 37
Study: 15598112

Group type: EXPERIMENTAL
Intervention: Activating abstract concepts (i.e., crime and basketball)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social group member representation
Number of subjects: 0
Study: 11277275

Group type: EXPERIMENTAL
Intervention: Calcitriol (1,25‐dihydroxyvitamin D3; 0.5 microg/day) for 6 months
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate plus calcium for 6 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Untreated reference group
Number of subjects: 41
Study: 10442545

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (beclomethasone dipropionate nasal spray, betamethasone nasal drops)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunisolide and budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (long-term therapy)
Number of subjects: 0
Study: 8085929

Group type: EXPERIMENTAL
Intervention: Electrical stimulation during continuous passive motion (CPM) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 40
Study: 2670693

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha 2A (Roferon‐A) at a dosage of 10 million units (MU)/m2 thrice weekly for six months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lower doses of interferon (5 MU/m2 and 2.5 MU/m2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study: 1066825

Group type: EXPERIMENTAL
Intervention: Supervised daily dental and oral care
Number of subjects: 149
Study: 31984760

Group type: EXPERIMENTAL
Intervention: URF‐Y0016
Number of subjects: 25

Group type: COMPARATOR
Intervention: URF‐P6
Number of subjects: 25
Study: 31302340

Group type: COMPARATOR
Intervention: Pidotimod alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pidotimod plus bifidobacteria
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bifidobacteria alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 100
Study: 27898207

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya yoga (SKY)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 25
Study: 26066789

Group type: EXPERIMENTAL
Intervention: Sulfonylureas (SUs)
Number of subjects: 59